Cyclo Therapeutics Inc (CYTH)

Jan 14, 2025, 8:05 AM EST - 3 days ago

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Dec 20, 2024, 12:15 PM EST - 4 weeks ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

SKGR

Nov 21, 2024, 4:13 AM EST - 2 months ago

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Nov 14, 2024, 8:05 AM EST - 2 months ago

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 5, 2024, 9:05 AM EDT - 4 months ago

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Aug 26, 2024, 5:41 PM EDT - 5 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

RFL

Aug 22, 2024, 10:19 AM EDT - 5 months ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

RFL

Aug 22, 2024, 6:50 AM EDT - 5 months ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

RFL

Aug 15, 2024, 9:00 AM EDT - 5 months ago

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 9:05 AM EDT - 6 months ago

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Jun 25, 2024, 9:25 AM EDT - 7 months ago

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

May 30, 2024, 9:00 AM EDT - 8 months ago

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

May 16, 2024, 8:05 AM EDT - 8 months ago

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 18, 2024, 9:05 AM EDT - 10 months ago

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 14, 2024, 9:34 AM EDT - 11 months ago

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Jan 29, 2024, 9:15 AM EST - 1 year ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Dec 27, 2023, 4:15 PM EST - 1 year ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Dec 18, 2023, 9:15 AM EST - 1 year ago

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Nov 28, 2023, 5:19 PM EST - 1 year ago

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Nov 21, 2023, 8:05 AM EST - 1 year ago

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Nov 15, 2023, 8:05 AM EST - 1 year ago

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Oct 5, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Sep 21, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Aug 15, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 1 year ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

RFL

Jun 29, 2023, 1:32 PM EDT - 1 year ago

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Jun 12, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Jun 5, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

RFL

May 15, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 2, 2023, 8:12 AM EDT - 1 year ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

RFL

Apr 21, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2023, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Jan 11, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Jan 10, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 9, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Jan 4, 2023, 4:05 PM EST - 2 years ago

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 4, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Dec 30, 2022, 8:00 AM EST - 2 years ago

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Nov 11, 2022, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Oct 18, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Oct 4, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Sep 28, 2022, 2:02 PM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update

Sep 7, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics to Present at the China NPC Association Meeting

Jul 21, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Jul 11, 2022, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022